APLT

Applied Therapeutics Inc

Add to Watchlist

Advanced Chart

0.476

+0.041(9.432%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.4796

Open

0.450

VWAP

0.46

Vol

1.41M

Mkt Cap

68.52M

Low

0.4356

Amount

654.00K

EV/EBITDA(TTM)

Total Shares

114.27M

36.94M

EV/OCF(TTM)

P/S(TTM)

568.88

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-0.140

-70.83%

-0.143

-143.43%

-0.160

+6.67%

Estimates Revision

The market is revising Downward the revenue expectations for Applied Therapeutics, Inc. (APLT) for FY2025, with the revenue forecasts being adjusted by -89.13% over the past three months. During the same period, the stock price has changed by 58.60%.

Revenue Estimates for FY2025

Revise Downward

-89.13%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-4.97%

In Past 3 Month

Stock Price

Go Up

+58.60%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast APLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLT is 2.25 USD with a low forecast of 1.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.476

Low

1.50

Averages

2.25

High

3.00

Current: 0.476

Low

1.50

Averages

2.25

High

3.00

William Blair

Sami Corwin

Buy

Hold

Downgrades

n/a

2024-12-23

Reason

William Blair

Sami Corwin

Price Target

n/a

2024-12-23

Downgrades

Buy

Hold

Reason

William Blair downgraded Applied Therapeutics to Market Perform from Outperform.

RBC Capital

Brian Abrahams

Hold

Maintains

$4 → $1.5

2024-12-20

Reason

RBC Capital

Brian Abrahams

Price Target

$4 → $1.5

2024-12-20

Maintains

Hold

Reason

RBC Capital analyst Brian Abrahams lowered the firm's price target on Applied Therapeutics to $1.50 from $4 and keeps a Sector Perform rating on the shares. The content of the FDA's recent Warning Letter raises additional questions about data integrity and increases overall risk to the company's govorestat development path across indications, the analyst tells investors in a research note. While there have been some signals of activity for the drug and FDA has pushed for greater flexibility around rare disease approvals, with this added layer of uncertainty, Applied Therapeutics shares may trade more in-line near term, the firm adds.

UBS

Esther Rajavelu

Strong Buy

Hold

Downgrades

$13 → $2

2024-12-02

Reason

UBS

Esther Rajavelu

Price Target

$13 → $2

2024-12-02

Downgrades

Strong Buy

Hold

Reason

UBS analyst Colin Bristow downgraded Applied Therapeutics to Neutral from Buy with a price target of $2, down from $13.

Citigroup

Yigal Nochomovitz

Strong Buy

Maintains

$13 → $8

2024-11-29

Reason

Citigroup

Yigal Nochomovitz

Price Target

$13 → $8

2024-11-29

Maintains

Strong Buy

Reason

Citi raised the firm's price target on Applied Therapeutics to $13 from $11 and keeps a Buy rating on the shares after having updated its model for reported Q3 financial results. The firm notes it currently has a positive catalyst watch for the approval of govorestat in galactosemia and continues to see 85% odds of success. Assuming the potential FDA approval this week, leading to initial revenue production in 2025, plus the option to monetize the associated PRV, the firm believes the company could reach cash flow breakeven in 2026, the analyst noted.

RBC Capital

Brian Abrahams

Buy

Hold

Downgrades

$12 → $4

2024-11-29

Reason

RBC Capital

Brian Abrahams

Price Target

$12 → $4

2024-11-29

Downgrades

Buy

Hold

Reason

RBC Capital notes that Applied Therapeutics' PDUFA for govorestat is tomorrow, November 28th, though given that the day falls on a holiday, there is some uncertainty around when a potential decision could be announced. The firm's analysis of PDUFAs that fall on weekday federal holidays shows that 100% of approvals get announced ahead of holidays and the only CRL was announced after - suggesting that if govorestat were to be approved, one would likely hear sometime today. Recall that RBC had previously done a similar analysis of PDUFAs that fell on weekends, and its conclusion had been that approvals are more likely to come prior to the PDUFA date with the vast majority of CRLs announced after. The firm caveats that sample sizes for holiday PDUFAs are small, but together with its weekend analysis, the firm continues to believe that good news typically tends to come early, and that if govorestat is not approved by today, that there could be a higher chance the drug may receive a CRL. RBC has an Outperform rating on the shares with a price target of $12.

Baird

Brian Skorney

Buy

Maintains

$14 → $5

2024-11-29

Reason

Baird

Brian Skorney

Price Target

$14 → $5

2024-11-29

Maintains

Buy

Reason

Baird analyst Brian Skorney lowered the firm's price target on Applied Therapeutics to $5 from $14 and keeps an Outperform rating on the shares after the FDA issued a complete response letter for govorestat for the treatment of galactosemia. The "credibility damage will be tough to bounce back from" there is a lack of substantial detail around how the review went south, the analyst tells investors in a research note. The firm now expects the review in sorbitol dehydrogenase deficiency to be "greeted with much greater skepticism by investors." However, it remains an attractive a commercial opportunity as galactosemia and the stock could rally back in the double-digits after an approval next year, contends Baird.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Applied Therapeutics Inc (APLT.O) is -0.78, compared to its 5-year average forward P/E of -3.26. For a more detailed relative valuation and DCF analysis to assess Applied Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.26

Current PE

-0.78

Overvalued PE

0.16

Undervalued PE

-6.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.45

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.52

Undervalued EV/EBITDA

-6.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

87.17

Current PS

0.00

Overvalued PS

338.16

Undervalued PS

-163.82

Financials

Annual

Quarterly

FY2025Q2

YoY :

-100.00%

0.00

Total Revenue

FY2025Q2

YoY :

+13.00%

-23.10M

Operating Profit

FY2025Q2

YoY :

-836.02%

-21.33M

Net Income after Tax

FY2025Q2

YoY :

-850.00%

-0.15

EPS - Diluted

FY2025Q2

N/A

Free Cash Flow

FY2025Q2

YoY :

-100.00%

N/A

Gross Profit Margin - %

FY2025Q2

YoY :

-100.00%

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

94.8K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

4.4M

Volume

6-9

Months

7.2M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

10.5M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

94.8K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

APLT News & Events

Events Timeline

2025-08-13 (ET)

2025-08-13

17:14:52

Applied Therapeutics reports Q2 EPS (15c), consensus (16c)

2025-06-17 (ET)

2025-06-17

16:14:52

Applied Therapeutics CMO Riccardo Perfetti to depart, Evan Bailey to succeed

2025-05-13 (ET)

2025-05-13

17:01:50

Applied Therapeutics reports Q1 EPS (15c), consensus (18c)

News

7.0

09-17Globenewswire

Crucial Update for Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT), DoubleVerify Holdings, Inc. (NYSE: DV), Elevance Health Inc. (NYSE: ELV), and V.F. Corp. (NYSE: VFC): Grabar Law Office is Looking into Claims for You

7.0

09-15Globenewswire

Crucial Update for Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT), DoubleVerify Holdings, Inc. (NYSE: DV), Ibotta Inc. (NYSE: IBTA), and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Looking into Claims for You

7.0

09-12Globenewswire

Crucial Update for Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT), DoubleVerify Holdings, Inc. (NYSE: DV), LuxUrban Hotels Inc. (OTC: LUXH), and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Looking into Claims for You